To investigate the impact of Rylaze on cell growth, we treated six human AML cell lines that harbor different cytogenetic and mutational burdens (MOLM-14, MV4-11, U937, HL60, K562, and Monomac-6) (6, 7) and two murine lines (Ba/F3 WT and FLT3-ITD) with increasing doses of Rylaze. Here, FLT3 is linked to acute myeloid leukemia.